D. Drake

发表

Activation of CNS Inflammatory Pathways by Interferon-alpha: Relationship to Monoamines and Depression

D. F. Drake, G. Pagnoni, Andrew H. Miller, 2022 .

Decreased Basal Ganglia Activation in Subjects with Chronic Fatigue Syndrome: Association with Symptoms of Fatigue

James F. Jones, D. F. Drake, G. Pagnoni, 2014, PloS one.

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.

D. F. Drake, P. Schettler, Andrew H. Miller, 2013, JAMA psychiatry.

Chronic Interferon-α Decreases Dopamine 2 Receptor Binding and Striatal Dopamine Release in Association with Anhedonia-Like Behavior in Nonhuman Primates

D. F. Drake, J. Nye, M. Goodman, 2013, Neuropsychopharmacology.

Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration.

D. F. Drake, G. Pagnoni, J. Votaw, 2012, Archives of general psychiatry.

Activation of Central Nervous System Inflammatory Pathways by Interferon-Alpha: Relationship to Monoamines and Depression

D. F. Drake, G. Pagnoni, Andrew H. Miller, 2009, Biological Psychiatry.

Neuroimaging statistical approaches for determining neural correlates of Alzheimer's disease via positron emission tomography imaging

D. F. Drake, G. Derado, D. Drake, 2023, WIREs Computational Statistics.

176. The tumor necrosis factor-alpha antagonist infliximab reduces depressive symptoms in patients with treatment resistant depression and high inflammation

A. Miller, C. Raison, E. Haroon, 2012, Brain, behavior, and immunity.